FY2028 EPS Forecast for OS Therapies Lowered by Analyst

OS Therapies Incorporated (NYSEAMERICAN:OSTX) – Investment analysts at Brookline Capital Management cut their FY2028 earnings per share (EPS) estimates for shares of OS Therapies in a report issued on Tuesday, November 18th. Brookline Capital Management analyst K. Raja now expects that the company will post earnings of $0.09 per share for the year, down from their prior estimate of $0.14. The consensus estimate for OS Therapies’ current full-year earnings is ($0.64) per share.

OS Therapies (NYSEAMERICAN:OSTX) last announced its quarterly earnings data on Friday, November 14th. The company reported ($0.21) earnings per share (EPS) for the quarter.

A number of other research firms also recently issued reports on OSTX. Zacks Research upgraded shares of OS Therapies from a “strong sell” rating to a “hold” rating in a research report on Tuesday, November 11th. Lake Street Capital dropped their price objective on shares of OS Therapies from $18.00 to $17.00 and set a “buy” rating on the stock in a research note on Tuesday. Finally, D. Boral Capital restated a “buy” rating and issued a $20.00 target price on shares of OS Therapies in a research note on Monday. Three research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat.com, OS Therapies has an average rating of “Moderate Buy” and an average target price of $17.33.

OS Therapies Price Performance

OSTX stock opened at $1.73 on Wednesday. The firm has a market cap of $60.91 million, a price-to-earnings ratio of -2.11 and a beta of -4.10. OS Therapies has a 1-year low of $1.12 and a 1-year high of $7.00. The firm has a fifty day moving average price of $1.97 and a two-hundred day moving average price of $1.90.

Institutional Investors Weigh In On OS Therapies

A number of hedge funds have recently made changes to their positions in the business. Susquehanna International Group LLP acquired a new position in shares of OS Therapies during the third quarter worth approximately $29,000. Mercer Global Advisors Inc. ADV acquired a new position in OS Therapies during the 3rd quarter worth $40,000. Ground Swell Capital LLC acquired a new position in OS Therapies during the 3rd quarter worth $40,000. Bridgeway Capital Management LLC bought a new position in shares of OS Therapies in the second quarter worth $47,000. Finally, CM Management LLC increased its holdings in shares of OS Therapies by 6.7% during the third quarter. CM Management LLC now owns 400,000 shares of the company’s stock valued at $784,000 after purchasing an additional 25,000 shares during the period.

About OS Therapies

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers.